Clinical Trial: Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury

Brief Summary:

RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy.

PURPOSE: This research study is measuring levels of TGF-beta in patients with epithelial cancers who are undergoing radiation therapy.


Detailed Summary:

OBJECTIVES:

  • To determine whether there is a dose-dependent increase in TGF-beta following radiotherapy in patients with epithelial cancers.

OUTLINE: Patients undergo blood sample collection prior to treatment, 24-72 hours after the first fraction of radiotherapy, and at the end of radiotherapy. Patients will also be asked for a weekly blood sample, but this is optional. Samples are analyzed to compare pre- and post-treatment TGF-beta levels.


Sponsor: Vanderbilt-Ingram Cancer Center

Current Primary Outcome: TGF-beta levels [ Time Frame: day 1 prior to treatment, 24-72 hours after 1st treatment, weekly at treatment (optional) and at completion of treatment ]

TGF-beta is a protein that can be detected in the blood.


Original Primary Outcome: TGF-beta levels

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Vanderbilt-Ingram Cancer Center

Dates:
Date Received: May 9, 2009
Date Started: January 2006
Date Completion:
Last Updated: April 10, 2013
Last Verified: April 2013